Christopher P Fox
Overview
Explore the profile of Christopher P Fox including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abramson J, Ku M, Hertzberg M, Huang H, Fox C, Zhang H, et al.
Lancet
. 2024 Nov;
404(10466):1940-1954.
PMID: 39550172
Background: Glofitamab monotherapy induces durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more previous therapies, but has not previously been assessed as a...
2.
Fox C, Townsend W, Gribben J, Menne T, Kalakonda N, Williams P, et al.
EJHaem
. 2024 Oct;
5(5):992-997.
PMID: 39415902
Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes...
3.
Bielack S, Soussain C, Fox C, Houillier C, Murciano T, Osborne W, et al.
J Cancer Res Clin Oncol
. 2024 Oct;
150(10):441.
PMID: 39356310
High-dose methotrexate (HDMTX) is used in the treatment of a range of adult and childhood cancers. Although HDMTX can provide effective anti-tumor activity with an acceptable safety profile for most...
4.
Wilson M, Cwynarski K, Eyre T, Smith J, Chaganti S, Fox C, et al.
Br J Haematol
. 2024 Aug;
205(6):2198-2205.
PMID: 39128894
This Good Practice Paper provides recommendations for the baseline investigation, risk stratification and use of prophylactic interventions for patients with large B-cell lymphoma at risk of central nervous system relapse....
5.
Ferreri A, Illerhaus G, Doorduijn J, Auer D, Bromberg J, Calimeri T, et al.
Hemasphere
. 2024 Jun;
8(6):e89.
PMID: 38836097
This EHA-ESMO Clinical Practice Guideline provides key recommendations for managing primary DLBCL of the CNS.The guideline covers clinical, imaging and pathological diagnosis, staging and risk assessment, treatment and follow-up.Algorithms for...
6.
Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, et al.
Lancet Haematol
. 2024 May;
11(6):e406-e414.
PMID: 38796193
Background: Follicular helper T-cell lymphomas (TFHL) harbour frequent alterations in genes that regulate DNA methylation. Preliminary reports suggest that treatment with 5-azacitidine has clinical activity in patients with relapsed or...
7.
Chaganti S, Maycock S, McIlroy G, Jackson A, Bishop R, Johnson S, et al.
Blood
. 2024 Apr;
144(4):392-401.
PMID: 38643491
Posttransplant lymphoproliferative disorder (PTLD) is a rare complication of solid organ transplantation, and cytotoxic chemotherapy is associated with treatment-related morbidity and mortality. Current treatment takes a sequential, risk-stratified approach, and...
8.
Fuller A, Hancox J, Williams H, Card T, Taal M, Aithal G, et al.
Rheumatology (Oxford)
. 2024 Mar;
64(3):969-975.
PMID: 38483276
Objective: To explore the acceptability of an individualized risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s). Methods: Adults (≥18 years)...
9.
Abhishek A, Grainge M, Card T, Williams H, Taal M, Aithal G, et al.
RMD Open
. 2024 Mar;
10(1).
PMID: 38453215
Background: Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping monitoring after 1...
10.
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline
Fox C, Chaganti S, McIlroy G, Barrington S, Burton C, Cwynarski K, et al.
Br J Haematol
. 2024 Jan;
204(4):1178-1192.
PMID: 38247115
No abstract available.